SID 2026Abstract 0461
Anifrolumab is associated with lower infection risk and improved skin activity in refractory cutaneous lupus compared to conventional immunosuppressants
Srikumar A, Urbanski N, Kang J
SID Annual Meeting 2026Chicago, 13–16 May 2026 · published in JID 21 Jul 2026
Topics: Autoimmune & connective tissueInfections & infestations
Abstract
The abstract’s text is on the JID website.
DOI 10.1016/j.jid.2026.06.492 · Not in PubMed: details from Crossref